The FDA on September 12, 2024, approved TECENTRIQ HYBREZA® for subcutaneous injection for all the adult indications as the intravenous formulation of TECENTRIQ®, including Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), HepatoCellular Carcinoma (HCC), Melanoma, and Alveolar Soft Part Sarcoma (ASPS). Both TECENTRIQ® and TECENTRIQ HYBREZA® are products of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
